Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Cannon CP, et al. Among authors: stepanavage m. N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17. N Engl J Med. 2010. PMID: 21082868 Free article. Clinical Trial.
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Cannon CP, Dansky HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators. Cannon CP, et al. Among authors: stepanavage m. Am Heart J. 2009 Oct;158(4):513-519.e3. doi: 10.1016/j.ahj.2009.07.028. Am Heart J. 2009. PMID: 19781408 Clinical Trial.
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM. Davidson M, et al. Among authors: stepanavage m. J Lipid Res. 2013 Feb;54(2):467-72. doi: 10.1194/jlr.M032615. Epub 2012 Nov 19. J Lipid Res. 2013. PMID: 23172660 Free PMC article.
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
Ose L, Davidson MH, Stein EA, Kastelein JJ, Scott RS, Hunninghake DB, Campodonico S, Insull W, Escobar ID, Schrott HG, Stepanavage ME, Wu M, Tate AC, Melino MR, Mercuri M, Mitchel YB. Ose L, et al. Among authors: stepanavage me. Clin Cardiol. 2000 Jan;23(1):39-46. doi: 10.1002/clc.4960230108. Clin Cardiol. 2000. PMID: 10680028 Free PMC article. Clinical Trial.
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W Jr, Bertolami M, Weiss SR, Kastelein JJ, Scott RS, Campodónico S, Escobar ID, Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC, Melino MR, Kush D, Mercuri M, Mitchel YB; Worldwide Expanded Dose Simvastatin Study Group. Davidson MH, et al. Among authors: stepanavage me. Nutr Metab Cardiovasc Dis. 2000 Oct;10(5):253-62. Nutr Metab Cardiovasc Dis. 2000. PMID: 11213534
Striated muscle safety of ezetimibe/simvastatin (Vytorin).
Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Davidson MH, et al. Among authors: stepanavage m. Am J Cardiol. 2006 Jan 15;97(2):223-8. doi: 10.1016/j.amjcard.2005.08.038. Epub 2005 Nov 21. Am J Cardiol. 2006. PMID: 16442367
19 results